Tests:Tobramycin, Serum: Difference between revisions
Tests:Tobramycin, Serum
Updated |
Updated method Alinity |
||
| (One intermediate revision by one other user not shown) | |||
| Line 77: | Line 77: | ||
|- | |- | ||
|Test Method | |Test Method | ||
|Abbott Alinity | |Abbott Alinity c series analyser using Abbott reagents. | ||
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA) | |||
|- | |- | ||
|Advanced Notice | |Advanced Notice | ||
| Line 91: | Line 92: | ||
Aminoglycoside clearance is reduced with renal impairment. | Aminoglycoside clearance is reduced with renal impairment. | ||
|} | |} | ||
{{DocMeta | |||
| owner = Crossley1 | |||
| review_ping = | |||
}} | |||
Latest revision as of 11:18, 30 January 2026
Overview | |
|---|---|
| Department | Biochemistry |
| Test Code | TOBR |
| Synonyms | Nebcin |
| Availability | Monday - Sunday, testing routinely available out of hours |
| Turnaround Time | 1 – 4hrs |
| Stability – Add test | 24 hours |
Specimen Requirements | |
| Patient Preparation | Please supply last dosage details (Start time, date, and dosage amount) |
| Specimen | Serum
Plasma |
| Preferred | Li-Hep Green-Top tube |
| Acceptable | Red-Top or Yellow-Top tube |
| Unacceptable | |
| Specimen Transportation | |
| Paediatric Requirements | 600uL Li-Hep Microtainer |
Aliquot Requirements | |
| Sample | Plasma
Serum |
| Preferred Volume | 0.5 mL |
| Minimum Volume | 0.2 mL |
| Aliquot Transportation | |
Clinical Information | |
| Reference Intervals | Trough level: 0 - 2 mg/L
Peak level: 5 - 10 mg/L |
| Test Method | Abbott Alinity c series analyser using Abbott reagents.
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA) |
| Advanced Notice | Please notify the laboratory in advance of any scheduled testing – extn 7881 |
Comments | |
| Telephone communication about impending requests will greatly facilitate rapid results.
Once daily dosing is recommended using a target area-under-the-concentration (AUC) curve. Contact the ward Pharmacist. Aminoglycoside clearance is reduced with renal impairment. | |
| Owner | Clair Crossley (Crossley1) |
|---|---|
| Last reviewed | 30.01.2026 |
| Next review | 30.01.2027 (OK) |